Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | XBP1 | P17861 | 1/20 | 0.55 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5666838 | 0.89 | P2RX1 (0.69) | MEN1KMT2ARAB9AP2RX1MAPT | |
| SCHEMBL31583073 | 0.87 | P2RX1 (0.66) | MEN1KMT2ARAB9AP2RX1MAPT | |
| SCHEMBL5668773 | 0.87 | P2RX1 (0.66) | MEN1KMT2ARAB9AP2RX1MAPT | |
| SCHEMBL5666676 | 0.86 | MEN1 (0.65) | MEN1KMT2ARAB9AP2RX1MAPT | |
| SCHEMBL5900771 | 0.86 | MEN1 (0.65) | MEN1KMT2ARAB9AP2RX1MAPT | |
| SCHEMBL5668756 | 0.84 | P2RX1 (0.66) | MEN1KMT2ARAB9AP2RX1MAPT | |
| SCHEMBL4960624 | 0.84 | P2RX1 (0.62) | MEN1KMT2ARAB9AP2RX1MAPT | |
| SCHEMBL4960611 | 0.84 | P2RX1 (0.62) | MEN1KMT2ARAB9AP2RX1MAPT | |
| SCHEMBL4960684 | 0.81 | P2RX1 (0.59) | MEN1KMT2ARAB9AP2RX1MAPT | |
| SCHEMBL4960692 | 0.81 | P2RX1 (0.59) | MEN1KMT2ARAB9AP2RX1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2269988-B1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2012-05-23 | — | — | EP | disclosed |
| EP-1446382-B1 | ANTHRANILIC ACID AMIDES AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| EP-1446381-B1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269988-A2 | Anthranilic acid amides and pharmaceutical use thereof | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-1572686-B1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| US-7482369-B2 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2009-01-27 | — | — | US | disclosed |
| US-7091224-B2 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2006-08-15 | — | — | US | disclosed |
| US-20060178409-A1 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | BOLD GUIDO | 2006-08-10 | — | — | US | disclosed |
| US-7067543-B2 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | BOLD GUIDO | 2006-06-15 | — | — | US | disclosed |
| EP-1572686-A1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | Novartis AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| US-20050096356-A1 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-05-05 | — | — | US | disclosed |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1446381-A1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | Novartis AG (CH) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004052884-A1 | ANTHRANILIC ACID AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | disclosed |
| WO-2003040101-A1 | ANTHRANILIC ACID AMIDES AND PHARMACEUTICAL USE THEREOF | NOVARTIS AG (CH) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178409-A1 | Anthranilic acid amides and their use as VEGF receptor tyrosine kinase inhibitors | AXL, FLT1, KDR | MEN1 3946/4885KMT2A 3117/4885RAB9A 1688/4885 |
| US-20040248947-A1 | Anthranilic acid amides and pharmaceutical use thereof | AFF1, FFAR1, FFAR2 | MEN1 1794/4885KMT2A 2640/4885RAB9A 1291/4885 |
| US-20060128684-A1 | Anthranilic acid amide derivatives and their pharmaceutical use | AADAC, AADAT, NAAA | MEN1 2649/4885KMT2A 888/4885RAB9A 1213/4885 |
| US-20050096356-A1 | Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors | AXL, FLT1, KDR | MEN1 3675/4885KMT2A 2850/4885RAB9A 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.